hVIVO plc (AIM:HVO)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 35.22M -20.4% |
| Revenue (ttm) | 42.09M -22.7% |
| Net Income | -12.21M |
| EPS | -0.02 |
| Shares Out | 687.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 700,622 |
| Open | 5.40 |
| Previous Close | 5.35 |
| Day's Range | 5.10 - 5.40 |
| 52-Week Range | 4.31 - 11.00 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 15.50 (+202.35%) |
| Est. Earnings | Dec 16, 2026 |
About hVIVO
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for HVO stock is "Buy." The 12-month stock price target is 16p, which is an increase of 202.35% from the latest price.
News
hVIVO Earnings Call Transcript: H1 2026
Revenue for H1 2026 declined to GBP 16.3 million due to HCT contract delays, resulting in an EBITDA loss, but a record GBP 72 million order book and diversification into new service lines and geographies support strong visibility and projected growth for 2027. CRS Berlin acquisition is immediately accretive, and H2 2026 is expected to see nearly double the revenue of H1.
hVIVO Quarterly report: H1 2026
hVIVO has published its H1 2026 quarterly earnings report on September 15, 2026.
hVIVO Slides: H1 2026
hVIVO has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 15, 2026.
hVIVO Earnings release: H1 2026
hVIVO released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
hVIVO Transcript: CMD 2026
The company has transformed into a fully integrated clinical development platform, expanding its service lines, geographic reach, and technological capabilities. Diversification and strategic partnerships have driven growth, with notable success in respiratory and cardiometabolic research, and a strong pipeline supported by repeat business and regulatory recognition of challenge trials.
hVIVO Slides: FY 2026
hVIVO has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 11, 2026.
hVIVO Earnings Call Transcript: H2 2025
2025 saw financial challenges from trial cancellations, but operational progress included acquisitions, rebranding, and diversification into new clinical and geographic areas. Human challenge trials remain core, but non-challenge revenue now exceeds 50%, supporting a strong outlook for 2026.
hVIVO Annual report: H2 2025
hVIVO has published its H2 2025 annual report on April 15, 2026.
hVIVO Slides: H2 2025
hVIVO has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 15, 2026.
hVIVO Annual report: H2 2025
hVIVO has published its H2 2025 annual report on April 15, 2026.
hVIVO Earnings Call Transcript: Q4 2025
FY25 revenue met guidance at GBP 46.7m, with positive EBITDA margin and strong cash position. Acquisitions expanded services and geographic reach, while diversification reduced reliance on HCT. Guidance for 2026 is high single-digit growth, supported by a robust pipeline.
hVIVO Earnings release: Q4 2025
hVIVO released its Q4 2025 earnings on January 29, 2026, summarizing the period's financial results.
hVIVO Slides: Q4 2025
hVIVO has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 29, 2026.
hVIVO upgraded to Buy from Add at Peel Hunt
Peel Hunt analyst Miles Dixon upgraded hVIVO (OPORF) to Buy from Add with a 10 GBp price target
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis vaccine to protect against whooping cough, today a...